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Abstract
Background: T-cell based immunotherapy for lung cancer (LC) could be a promising and novel therapeutic
approach. Six-transmembrane epithelial antigen of the prostate (STEAP) and the polycomb group protein enhancer
of zeste homolog 2 (EZH2) are highly expressed in LC and since the expression of molecules in normal tissue is
significantly lower as compared to tumor cells, these proteins are considered as potential tumor-associated
antigens (TAAs) for developing T-cell based immunotherapy.
Methods: We assessed the capacity of predicted CD4 T-cell epitopes from STEAP and EZH2 to induce anti-tumor
immune responses to LC cell lines.
Results: Out of several predicted epitopes, two synthetic peptides, STEAP281-296 and EZH295-109, were effective in
inducing CD4 T-cell responses that were restricted by HLA-DR1, DR15, or DR53 molecules, indicating that the
peptides function as promiscuous T-cell epitopes. Moreover, STEAP281-296 and EZH295-109-reactive T-cells could
directly recognize STEAP or EZH2 expressing LC cells in an HLA-DR restricted manner. In addition, some STEAP-
reactive T-cells responded to STEAP+ tumor cell lysates presented by autologous dendric cells. Most significantly,
both of these peptides were capable of stimulating in vitro T-cell responses in patients with LC.
Conclusions: Peptides STEAP281-296 and EZH295-109 function as strong CD4 T-cell epitopes that can elicit effective
anti-tumor T-cell responses against STEAP or EZH2 expressing LC. These observations may facilitate the translation
of T-cell based immunotherapy into the clinic for the treatment of LC.
Background
Lung cancer (LC) represents a significant health pro-
blem with 222,520 new cases and 157,300 deaths in the
past 10 years in the United States [1]. Recently, adjuvant
cisplatin-vinorelbine chemotherapy in completely
resected non-small cell LC (NSCLC) has resulted in an
enhanced survival benefit at 5 years (8.9% improvement
versus observation) [2]. Molecular target-based drugs
(gefitinib, erlotinib, etc.) are available for specific types
of NSCLC showing epidermal growth factor receptor
mutations. However, these chemotherapeutic regimens
can be extremely toxic and provide limited survival ben-
efit for advanced LC. Thus, the development of novel
and less toxic alternatives such as immunotherapy is
warranted. Nevertheless, the success of immunotherapy
will ultimately rely on the identification of appropriate
tumor-associated antigens (TAAs) that are overex-
pressed in tumor cells relative to normal tissues.
Six-transmembrane epithelial antigen of the prostate
(STEAP) is a 339 amino acid protein that is critical for
erythroid iron homeostasis. STEAP is located on the cell
surface [3] and is predominantly overexpressed in various
tumor types (prostate, bladder, colon, ovarian, and Ewing
sarcoma) [4]. The enhancer of zeste homolog 2 (EZH2) is
a polycomb group protein that functions as a regulator of
homeobox gene expression [5]. EZH2 is highly expressed
in various tumor types including prostate [6], breast [7],
esophagus [8], and pancreatic [9] cancers. Moreover, the
expression of EZH2 has been linked to tumor
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linked to a poor overall patient prognosis [6-8]. The low
expression of STEAP and EZH2 in normal tissues
together with recent studies reporting that these mole-
cules are overexpressed in NSCLC, suggests that both
protein could be utilized as TAAs in LC [10,11].
Although CD8 cytotoxic T lymphocytes are believed
to have a major role in eradicating cancer, CD4 helper
T lymphocytes are likely to have a critical role in immu-
notherapy since they participate in generation and per-
sistence of CD8 T-cell responses [12]. In addition, CD4
T-cells exhibit an effector role against tumors that
express HLA-DR molecules [13]. For the development
of peptide-based immunotherapies against LC, we have
searched for possible HLA-DR epitopes capable of elicit-
ing CD4 T-cell responses to STEAP and EZH2. Here,
we report that 2 epitopes, STEAP281-296 and EZH295-109
were capable of eliciting in vitro antigen-specific, HLA-
DR-restricted CD4 T-cell responses against LC cells
expressing STEAP and EZH2. In addition, peptides
STEAP281-296 and EZH295-109 were also found to stimu-
late T-cell responses in LC patients. We believe that
these results may be of use for the development of T-
cell based immunotherapy for LC.
Methods
Cell lines
Mouse fibroblast cell lines (L-cells) transfected and
expressing individual human HLA-DR molecules were
kindly provided by Dr. Robert W. Karr (Karr Pharma,
Saint. Louis, MO, USA) and by Dr. Takehiko Sasazuki
(Kyushu University, Fukuoka, Japan). The LC cell lines
PC14, A549, LC-2/ad, LCAM1 (adenocarcinomas), LK2,
RERF-LC-AI, EBC1 (squamous cell carcinomas), LU65,
and LU99 (large cell carcinomas) were supplied by the
RIKEN Bio-Resource Center (Tsukuba, Japan). The LC
cell lines LHK2 and 1-87 (adenocarcinomas) were kindly
provided by Dr. Yasuaki Tamura (Sapporo Medical Uni-
versity, Sapporo, Japan). Tumor cell lines H23, H441
(lung adenocarcinomas), H520, SK-MES-1, Calu-1 (lung
squamous cell carcinomas), PC3 (prostate cancer),
MCF7 (breast cancer), WiDr (colon carcinoma) and Jur-
kat (T cell lymphoma) were purchased from ATCC
(Manassas, VA, USA). All cell lines were maintained in
tissue culture as recommended by supplier.
Immunohistochemistry
An indirect immunoperoxidase technique (the streptavi-
din-biotin method) was performed. To detect STEAP,
polyclonal rabbit anti-human STEAP (ZMD.265, Zymed
Laboratories, Inc., South San Francisco, CA, USA), diluted
1:200, served as the primary antibody. To detect EZH2,
monoclonal mouse anti-human EZH2 (BD.612666, BD
Bioscience, San Jose, CA, USA), diluted 1:200, served as
the primary antibody. To detect HLA-DR, monoclonal
mouse anti-human HLA-DR a chain (TAL.1B5, DakoCy-
tomation, Denmark), diluted 1:10000, served as the pri-
mary antibody. We assessed STEAP, EZH2 and HLA-DR
expression in surgically resected LC specimens.
Western blotting
One million cells were washed in phosphate buffered sal-
ine (PBS) and lysed in NuPAGE LDS sample buffer (Invi-
trogen). The cell lysate was subjected to electrophoresis
in a 4-12% NuPAGE bis-Tris SDS-PAGE gel (Invitrogen)
under reducing condition and transferred to Immobilon-
P (Millipore, Bedford, MA, USA) membrane. The mem-
brane was blocked in PBS containing 0.01% Tween 20
and 5% non-fat dry milk for 1 h at room temperature and
incubated with rabbit anti-human STEAP polyclonal
antibody (H-105, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) diluted 1:200 in blocking buffer, anti-human
EZH2 mouse monoclonal antibody (mAb) (BD.612666,
BD Bioscience, San Jose, CA, USA) diluted 1:200, or anti-
b-actin mAb (C4, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) diluted 1:1,000 in blocking buffer as the con-
trol, for 18 h at 4°C. After washing, the membrane was
incubated with horseradish peroxidase-labeled sheep
anti-rabbit or -mouse IgG and subjected to the enhanced
chemiluminescence assay using the ECL detection system
(Amersham, Buckinghamshire, UK).
Synthetic peptides
Potential HLA-DR-restricted CD4 T-cell epitopes were
selected from the amino acid sequence of STEAP and
EZH2 using the computer-based algorithms peptide/
MHC binding for three common HLA-DR alleles
(DRB1*0101, DRB1*0401, DRB1*0701) developed by
Southwood et al. [14]. The predicted peptide epitopes
were synthesized by solid phase organic chemistry and
purified by high-performance liquid chromatography
(HPLC). The purity (> 80%) and identity of peptides
were assessed by HPLC and mass spectrometry, respec-
tively. The synthetic peptides used throughout this study
were STEAP261-275 (SLLLGTIHALIFAWN), STEAP281-
296 (KQFVWYTPPTFMIAVF), EZH295-109 (VIPLKTL-
NAVASVPI), EZH2220-234 (SDKIFEAISSMFPDK),
EZH2693-704 (PNCYAKVMMVNGDHR). These peptides
were selected on the basis of having top 10 scores for at
least 2 of the three HLA-DR alleles. The tetanus toxoid
(TT) 830-843 (QYIKANSKFIGITE) peptide was used as a
control universal epitope peptide, since it is presented
by multiple HLA-DR alleles [15].
In vitro induction of antigen-specific CD4 T-cell clones
with synthetic peptides
The procedure utilized for the generation of STEAP and
EZH2 reactive CD4 T-cell clones using peptide-
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nuclear cells (PBMCs) of human healthy individuals has
been described in detail [16]. Briefly, dendritic cells
(DCs) were produced from purified CD14 monocytes
(using antibody-coated magnetic microbeads from Mil-
tenyi Biotech, Auburn CA, USA) cultured for 7 days at
37°C in a humidified CO2 (5%) incubator in the pre-
sence of 50 ng/ml GM-CSF and 1,000 IU/ml IL-4. Pep-
tide-pulsed DCs (3 μg/ml for 2 h at room temperature)
were irradiated (4,200 rad) and co-cultured with autolo-
gous purified CD4 T-cells in 96-flat-bottomed-well cul-
ture plates. One week after peptide stimulation, the CD4
T-cells were restimulated in individual microcultures
with peptide-pulsed irradiated autologous PBMCs and 2
days later, recombinant human IL-2 was added at a final
concentration of 10 IU/ml. One week later, the T-cells
were tested for antigen reactivity using a cytokine-
release assay as described below. Those microcultures
exhibiting a significant response of cytokine-release to
peptide (at least 2.5-fold over background) were cloned
by limiting dilution and expanded in 24-well plates by
weekly restimulation with peptides and irradiated auto-
logous PBMCs. Complete culture medium for all proce-
dures consisted of AIM-V medium (Invitrogen/GIBCO,
Carlsbad, CA, USA) supplemented with 3% human male
AB serum. All blood samples were obtained after the
appropriate informed consent.
Measurement of antigen-specific responses with
established CD4 T-cell clones
CD4 T-cells (3 × 10
4/well) were mixed with irradiated
antigen-presenting cells (APCs) in the presence of var-
ious concentrations of antigen (peptides, tumor lysates)
in 96-well culture plates. APCs consisted of autologous
PBMCs (1 × 10
5/well), HLA-DR expressing L-cells (3 ×
10
4 well), autologous DCs (5 × 10
3/well) or LC cell lines
(3 × 10
4/well). The LC cell lines were previously treated
with IFN-g at 500 U/ml for 48 h to enhance HLA-DR
expression. The expression of HLA-DR molecules on
tumor cells was evaluated by flow cytometry using anti-
HLA-DR mAb conjugated with fluorescein isothiocya-
n a t e( B DP h a r m i n g e n ,S a nD i e g o ,C A ) .T u m o rc e l l
lysates were prepared by 3 freeze-thaw cycles of 1 × 10
8
tumor cells, resuspened in 1 ml of serum-free AIM-V
medium. Tumor cell lysates served as an antigen at 5 ×
10
5 cell equivalents/ml. Culture supernatants were col-
lected after 48 h for measuring antigen-induced lympho-
kine (IFN-g or GM-CSF) or granzyme B production by
the CD4 T-cells using ELISA kits (IFN-g and GM-CSF;
BD Pharmingen, San Diego, CA, USA, granzyme B;
Mabtech AB, Nacka Strand, Sweden). To demonstrate
antigen-specificity and HLA-DR restriction, blocking of
antigen-induced responses were assessed by adding anti-
HLA-DR mAb L243 (IgG2a prepared from supernatants
of the hybridoma HB-55 obtained from the ATCC) or
the anti-HLA-A/B/C mAb W6/32 (IgG2a, ATCC) at 10
μg/ml throughout the 48 h incubation period.
Cell-mediated cytotoxicity assays
Cytotoxic activity of CD4 T-cell clones was measured
using a colorimetric CytoTox 96 assay (Promega, Madi-
son, WI, USA). This system quantifies the release of lac-
tate dehydrogenase (LDH) from target cells. T-cells
were mixed with 2 × 10
4 target cells at different effector
to target (E:T) ratios in 96-round-bottomed-well plates.
After 6 h incubation at 37°C, 50 μl supernatant samples
were collected from each well to measure LDH content.
Measurement of peptide-specific responses in LC patients
PBMCs were isolated from fresh heparinized blood by
Ficoll-Hypaque centrifugation and washed twice with
RPMI 1640. PBMCs were resuspended in complete
medium and placed at 1.5 × 10
5 cells/well and cultured
in triplicate in 96-round-bottomed well plates in the
presence of 10 μg/ml peptide. Negative controls (in the
absence of peptide), were done in eight replicate sam-
ples. One week later, the cultures were restimulated
with peptide-pulsed (10 μg/ml) irradiated autologous
PBMCs (5 × 10
4/well). After 7 days of restimulation,
supernatants were harvested for examining the ability of
peptide-induced lymphokine production by the LC
patient’s PBMCs. The institutional ethics committee had
approved the study protocol and the appropriate
informed consent for blood donation was obtained from
all patients before blood sampling.
Results
Expression of STEAP and EZH2 in LC samples and tumor
cell lines
In immunohistochemistry studies with several surgical
specimens of LC, we observed moderate to strong stain-
ing with anti-STEAP antibody and anti-EZH2 mAbs.
Conversely, staining of adjacent normal tissues with
these antibodies was much weaker. STEAP was detected
in 8/8 cases of the adenocarcinoma and 6/6 squamous
cell carcinoma cases. EZH2 was detected in 5/5 cases of
the adenocarcinoma and in 5/5 squamous cell carci-
noma cases (examples are shown in Figure 1). In addi-
tion, we performed immunohistochemical staining for
expression of HLA-DR in 5 lung adenocarcinomas and
4 lung squamous cell carcinomas. We have found the
expression of HLA-DR in the adenocarcinoma cells (4/5
cases) and in the infiltrating APCs, lymphocytes and
alveolar macrophages (Figure 2). These observations
suggest that tumor cells could be logical targets of
STEAP- or EZH2-specific CD4 T-cells in situ.
Western blot analysis revealed that STEAP was pre-
sent in several tumor cell lines including LCs (except
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Figure 1 STEAP and EZH2 expression in LC specimens. (A) STEAP, adenocarcinoma (×400). (B) STEAP, squamous cell carcinoma (×400). (C)
EZH2, adenocarcinoma (×200). (D) EZH2, squamous cell carcinoma (×200).
$ %
Figure 2 HLA-DR expression in lung adenocarcinoma specimens. (A)(B) Adenocarcinoma cells and infiltrating APCs including lymphocytes
or alveolar macrophages are positive for HLA-DR (×200).
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control), but was absent in PBMC samples from healthy
individuals (Figure 3A). EZH2 was detected in all the
tumor cell lines (including Jurkat), but not in PBMCs
(Figure 3B). These observations provide a rationale for
exploring the use of STEAP and EZH2 as TAAs for
developing anti-tumor T-cell based immunotherapy for
LC (and the other tumor types).
Selection of potential HLA-class II restricted peptide
epitopes from EZH2 and STEAP
To identify the promiscuous (broadly degenerate) HLA-
class II binding peptide epitopes is very important since
using the degenerate epitope-based vaccines in applic-
able to general population. For predicting promiscuous
HLA-class II binding peptides, we used computer-based
MHC peptide binding motifs for three common HLA-
class II molecules, HLA-DR1, DR4 and DR7 [14]. In
addition, this algorithm indicate that some peptides that
score high for the DR1, DR4 and DR7 alleles also have
the capacity to bind to additional HLA-class II alleles
such as DR9, DR13, DR15 and DR53. Therefore, we
have reported that some peptides predicted by addi-
tional HLA-class II alleles, such as DR9, DR13, DR15 or
DR53 [17]. In this study, the prediction system could
select nine peptide sequences from EZH2 (data not
shown) and we selected the three highest potentially
promiscuous peptides, EZH295-109,E Z H 2 220-234 and
EZH2693-704. In the case of STEAP, the algorithm system
suggested 28 peptide sequences (data not shown) as
potentially promiscuous HLA-class II binders and we
have reported that two STEAP peptides, STEAP102-116
and STEAP192-206 were effective in stimulating in vitro
anti-tumor T helper responses [18,19]. In the present
study, considering that an ideal TAA should contain
peptide epitopes to stimulate both CD8 and CD4 T-
cells, we selected 2 STEAP peptides from these promis-
cuous binders, STEAP261-275, which overlaps with HLA-
A2-restricted CD8 T-cell epitope STEAP262-270 [20] and
STEAP281-296, which lies proximal to HLA-A2-restricted
CD8 epitope, STEAP292-300 [21]. We synthesized the
three EZH2 and two STEAP epitope peptides and pro-
ceeded to determine whether these peptides could
induce CD4 helper T-cell responses in vitro.
Induction of CD4 T-cell responses to STEAP and EZH2
peptide epitopes
Next, we evaluated whether these peptides were capable
of stimulating CD4 T-cells obtained from 6 healthy indi-
viduals (HLA-DR4/15, HLA-DR4/9, HLA-DR4/15, HLA-
DR1/15, HLA-DR9/13 and HLA-DR9/14) using autolo-
gous DCs as APCs. After 2-3 peptide restimulation
cycles, 2 of 5 peptides (STEAP281-296 and EZH295-109)
were able to induce peptide-specific CD4 T-cell
responses. To carry out more detailed antigen specificity
and HLA-DR restriction analyses, and to assess tumor
cell recognition, T-cell clones (4 reactive with
STEAP281-296 and 6 reactive with EZH295-109)w e r ei s o -
lated by limiting dilution. As shown in Figure 4, all of
these clones recognized their respective peptide epitopes
in a dose dependent manner and this recognition was
inhibited by anti-HLA-DR (L243) mAb but not by anti-
HLA-class I (W6/32) mAb. Since mAb L243 is specific
for HLA-DR, these results indicate that the presentation
of STEAP281-296 and EZH295-109 to the T-cells is via
HLA-DR molecules and not via other HLA-class II
molecules (HLA-DQ or DP). To more specifically
delineate the HLA-DR restriction alleles, we studied the
T-cells responses using a panel of HLA-DR transfected
mouse L-cells and HLA-typed human EBV-LCLs. As
s h o w ni nF i g u r e5 A ,t h eS T E A P 281-296-reactive clone
SH31 was restricted by HLA-DR15 molecules, and
STEAP  
STEAP  
ȕ-actin 
ȕ-actin 
EZH2  
EZH2  
ȕ-actin 
ȕ-actin 
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Figure 3 Expression of STEAP and EZH2 protein in various tumor cell lines. Western blotting was done using STEAP- or EZH2-specific
antibody as described in “Materials and methods”. The STEAP protein has a mass of approximately 36 kDa, and EZH2 protein 91 kDa. (A) STEAP,
(B) EZH2.
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but in the context of HLA-DR53. The EZH295-109 epi-
tope was presented to clone SK31 via HLA-DR1, to
clones SK32 and Sa361 by HLA-DR15 and to clones
MT10, Sa362 and YM18 by HLA-DR53 (Figure 5B, C
and 5D). These results indicate that STEAP281-296 and
EZH295-109 can be presented to CD4 T-cells by more
than one HLA-DR allele, behaving as classical promiscu-
ous epitopes.
Direct recognition of STEAP- or EZH2-expressing LC cells
by STEAP281-296- or EZH295-109-reactive CD4 T-cell clones
We then evaluated whether STEAP or EZH2 reactive
CD4 T-cell clones could directly recognize STEAP or
EZH2 expressing LC cells. Before this study, we first
measured cell surface HLA-DR expression in several
tumor cell lines that would be used in these studies.
The LC cell lines (LU65, LC-2/ad, RERF-LC-AI, EBC1,
Calu-1) displayed measurable levels of surface HLA-DR
after IFN-g treatment. However, there was no HLA-DR
expression in A549 lung adenocarcinoma and Jurkat T-
cell lymphoma (data not shown). The peptide-reactive
CD4 T-cell clones were then tested for reactivity (IFN-g
production) against the HLA-DR expressing, STEAP/
EZH2 positive LC cell lines. As shown in Figure 6A,
CD4 T-cell clone SH31 (STEAP281-296-reactive, DR15-
restricted) recognized two STEAP+/DR15+ LC tumors
(LU65, RERF-LC-AI). Similarly, the HLA-DR53-
restricted, STEAP281-296-reactive CD4 T-cell clones,
SH6, HK7 and Sa12 recognized STEAP+/DR53+ LC
tumors (LU65, Calu-1, Figure 6B, C and 6D). In addi-
tion, the STEAP281-296-reactive CD4 T-cell clones SH31
and Sa12 produced granzyme B (serine protease cyto-
toxic molecule) when stimulated with LC tumors in an
HLA-DR dependent manner (Figure 7A). In the case of
EZH2-reactive CD4 T-cell responses, clone SK31
$%
&'
Figure 4 HLA-DR restriction analysis of STEAP281-296-a n dE Z H 2 95-109-reactive CD4 T-cell clones. (A) L243 but not W6/32 inhibited IFN-g
production from HLA-DR restricted, STEAP281-296-reactive CD4 T-cell clones. (B) HLA-DR restriction analysis of EZH295-109-reactive CD4 T-cell
clones. (C and D) STEAP281-296- and EZH295-109-reactive CD4 T-cell clones were tested for their capacity to recognize autologous PBMCs as APCs
in the presence of various concentrations of peptide. Points means of triplicate determinations, bars SD. Points without bars had SD < 10% the
value of the mean. Results are representative of two experiments that were done with the same samples.
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EZH2+/DR1+ LC tumors (LU65, EBC1 and LC-2/ad,
Figure 8A). CD4 T-cell clones SK32 and Sa361
(EZH295-109-reactive, DR15-restricted) recognized EZH2
+/DR15+ LC tumors (LU65, RERF-LC-AI, Figure 8B
and 8C). Lastly, as shown in Figure 8D and 8E, CD4 T-
cell clones Sa362 and YM18 (EZH295-109-reactive,
DR53-restricted) were able to react with EZH2+/DR53+
LC tumors (LU65, Calu-1). Furthermore, the EZH295-
109-reactive CD4 T-cell clones produced granzyme B
when stimulate with LC cells (Figure 7B). Direct tumor
recognition in all cases was antigen-specific and HLA-
DR-restricted since tumor cell lines not expressing the
a p p r o p r i a t ea n t i g e n( S T E A P ,E Z H 2 ) ,a n dt h ec o r r e -
sponding HLA-DR molecule failed to stimulate the CD4
T-cell responses. Furthermore, the capacity of the
STEAP- and EZH2-expressing LC cells to activate the
CD4 T-cell clones was significantly inhibited by the
addition of anti-HLA-DR L243 mAb confirming that the
peptide epitopes were presented via HLA-DR molecules.
Recognition of naturally processed exogenous antigen by
STEAP-reactive CD4 T-cell clones
In addition, we assessed whether APCs such as DCs
could capture and process antigens derived from dead
STEAP expressing tumor cells (freeze-thaw cell
lysates) and present the STEAP epitope to the CD4 T-
cell clones. As shown in Figure 9, the STEAP281-296-
reactive CD4 T-cell clones SH31, SH6 and Sa12
recognized naturally processed epitope presented by
DCs derived from STEAP positive LC cell lysates
(LU65, A549, RERF-LC-AI) but not STEAP negative,
Jurkat cell lysates. These responses were inhibited by
L243 mAb (anti-HLA-DR) but not by W6/32 mAb
(anti-HLA-class I), indicating that CD4 T-cell
responses were antigen-specific and via the interaction
of T-cell receptor with HLA-DR molecules. These
results indicate that the STEAP281-296 epitope can be
presented to T-cells via either the endogenous (direct
tumor recognition) or exogenous (DCs) antigen pro-
cessing pathways.
$ %
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Figure 5 Definition of restricting HLA-DR alleles of the STEAP- or EZH2-reactive CD4 T-cell clones.I F N - g production of the STEAP281-296-
reactive CD4 T-cell clones (A) and EZH295-109-reactive CD4 T-cell clones (B, C, and D) was evaluated using L-cells or semi-allogenic EBV-LCLs
homozygous for HLA-DR molecules as APCs to define the restricting HLA-DR elements. Columns means of triplicate determinations, bars SD.
Columns without bars had SD < 10% the values of the mean. Results are representative of at least two experiments.
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unable to recognize naturally processed epitopes derived
from tumor cell lysates via DCs (data not shown).
Cytotoxic activity of STEAP- or EZH2-specific CD4 T-cell
clones
Having observed that peptide STEAP281-296 and
EZH295-109 elicited CD4 T-cell clones produced gran-
zyme B when stimulated with STEAP or EZH2 expres-
sing LC cells (Figure 7), we evaluated the cytotoxic
activity of the CD4 T-cell clones. The STEAP281-296-
reactive, DR15-restricted clones SH31 and Sa12 effec-
tively lysed STEAP expressing LC cell lines in a dose
dependent manner (Figure 10A). Similarly, the
EZH295-109-reactive clones SK32 and Sa361 and Sa362
were efficient in killing the EZH2 expressing LC cell
lines (Figure 10B).
STEAP and EZH2 peptide recognition by PBMCs from
patients with LC
Lastly, to further evaluate the capacity of LC patients
to exhibit CD4 T-cell responses to STEAP281-296 and
EZH295-109, we stimulated PBMCs from 10 LC patients
and 3 healthy donors with the corresponding peptides
in short-term cultures. Seven days after the second sti-
mulation, culture supernatants were collected and IFN-
g or GM-CSF production was assessed. Peptide TT830-
843 was used as a positive control since this antigen
has ability to induce strong CD4 T-cell responses in
the majority individuals regardless of their HLA-DR
alleles. The results presented in Table 1 show signifi-
cant T-cell responses to STEAP281-296 in 9/10 patients,
to EZH295-109 in all patients, and to the positive con-
trol TT830-843 in all patients. These results suggest that
T-cell precursors that are reactive with the STEAP and
$%
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Figure 6 Direct recognition of STEAP-expressing lung tumor cells by STEAP281-296-reactive CD4 T-cell clones. DR15-restricted CD4 T-cell
clone SH31 (A) and DR53-restricted CD4 T-cell clones SH6 (B), HK7 (C), and Sa12 (D) were tested for their capacity to recognize antigen directly
on STEAP positive LC cells that are either matched or mismatched for the restricting HLA-DR alleles. The HLA-DR-negative Jurkat was also used
as negative control. The antigen specificity of these responses was demonstrated by blocking tumor recognition with L243. Columns without
bars had SD < 10% the values of the mean. Results are representative of two separate experiments.
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with LC.
Discussion
T-cell based immunotherapy has become an accepted
treatment alternative for cancer. The presence of lym-
phocytic infiltrations in murine and human lung
tumors suggests that an immune reaction could
potentially help to control LC progression [22,23]. In
view of this, we believe that identifying TAAs and the
corresponding peptide epitopes capable of eliciting
anti-tumor T-cell responses will be critical to develop
peptide-based cancer immunotherapy. EZH2 plays a
role in cell cycle regulation and proliferation and
increased EZH2 expression has been correlated with
aggressive tumor behavior and poor survival in LC
[18]. STEAP is overexpressed in various types of
tumors including LC. In addition, it has been reported
that generation of CD4 or CD8 T lymphocytes recog-
nizing STEAP and EZH2 indicates that STEAP and
EZH2 could be potent TAAs for T-cell based immu-
notherapy [18-21,24].
The goal of the present study was to assess whether
STEAP and EZH2 could function as TAAs for LC, cap-
able of generating anti-tumor CD4 T-cell responses.
The results showed that two peptides, STEAP281-296 and
EZH295-109, were efficient in activating and expanding
CD4 T-cells obtained from healthy individuals and LC
patients. The results show that STEAP281-296 could be
presented to CD4 T-cells by either HLA-DR15 or DR53
and that EZH295-109 is presented in the context of DR1,
DR15 or DR53 (Figure 5). The HLA-DR53 molecule is
expressed by a large proportion of the population
(~50%) owing to its linked co-expression with the HLA-
DR4, DR7, and HLA-DR9 alleles [14]. Thus, each pep-
tide would provide broad coverage for clinical use. Most
significant was the demonstration that the CD4 T-cell
clones generated by STEAP281-296 and EZH295-109 were
capable of recognizing naturally processed antigen
directly on HLA-DR expressing tumor cells and that the
T-cells exhibited cytotoxicity against the tumor cells.
These findings suggest the possibility of direct therapeu-
tic benefit of CD4 anti-tumor T-cell responses indepen-
dent of CD8 T-cells. Both STEAP281-296 and EZH295-109
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Figure 7 Granzyme B production from STEAP281-296- or EZH295-109-reactive CD4 T-cell clones. STEAP281-296-reactive, DR15-restricted CD4 T-
cell clone SH31 (A, left) and DR53-restricted CD4 T-cell clone Sa12 (A, right) were able to secrete granzyme B reacting with STEAP+/HLA-DR
matched LC cells. EZH295-109-reactive, DR15-restricted CD4 T-cell clone SK32 (B, left) and Sa361 (B, middle), and DR53-restricted CD4 T-cell clone
Sa362 (B, right) were able to secrete granzyme B reacting with EZH2+/HLA-DR matched LC cells. The HLA-DR-negative Jurkat was also used as
negative controls. The antigen specificity of these responses was demonstrated by blocking tumor recognition with L243. Columns without bars
had SD < 10% the values of the mean. Results are representative of two separate experiments.
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Figure 8 Direct recognition of EZH2-expressing lung tumor cells by EZH295-109-reactive CD4 T-cell clones. DR1-restricted CD4 T-cell clone
SK31 (A), DR15-restricted CD4 T-cell clone SK32 (B), Sa362 (C), DR53-restricted CD4 T-cell clones Sa362 (D) and YM18 (E) were tested for their
capacity to recognize antigen directly on EZH2 positive LC cells that are either matched or mismatched for the restricting HLA-DR alleles. The
HLA-DR-negative Jurkat was also used as negative controls. The antigen specificity of these responses was demonstrated by blocking tumor
recognition with L243. Columns without bars had SD < 10% the values of the mean. Results are representative of two separate experiments.
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Figure 9 STEAP281-296-reactive CD4 T-cell recognize naturally processed exogenous antigen presented by autologous DCs. STEAP281-296-
reactive CD4 T-cell clones SH31 (A), SH6 (B), and Sa12 (C) were tested for their reactivity against STEAP positive LC cell (LU65, A549, and RERF-LC-
AI) lysates and STEAP negative Jurkat cell lysate when presented by autologous DCs. The capacity of L243 to inhibit these responses was
assessed to demonstrate that T-cell reactivity was through TCR/HLA interactions. Columns means of triplicate determinations, bars SD. Columns
without bars had SD < 10% the values of the mean. Results are representative of at two separate experiments.
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in LC patients indicating that T-cell precursors capable
of recognizing STEAP281-296 or EZH295-109 exist in both
healthy individuals and some patients with LC.
As with the many TAA such as CEA, PSA or Her2/
neu, message and protein levels of EZH2 or STEAP
appear to be low amounts in normal tissues. Our results
show that normal cells such as PBMCs and DCs were
not recognized by the STEAP or EZH2-reactive CD4 T-
cells. Furthermore, Western blot analysis revealed no
detectable STEAP or EZH2 expression in PBMCs and
no significant expression of STEAP or EZH2 was found
in normal tissues using immunohistochemical staining.
Thus, we believe that no significant autoimmune pathol-
ogy would be elicited if STEAP or EZH2 CD4 T-cell
epitopes were used for cancer immunotherapy. Never-
theless, it would be wise to assess in more detail the
levels of STEAP or EZH2 in other normal tissues (e.g.,
liver, kidney, brain) before setting about clinical trials
using STEAP or EZH2 as targets for immunotherapy.
It is possible that direct stimulation of T-cells, even
priming by tumor cells may be actually tolerant toward
TAAs. In fact, EZH2 and STEAP express in very low
amounts in normal tissues and benign neoplasms and
upregulated and overexpressed in malignant tumors.
These low- and high-level expressions may induce toler-
ance by deletion of the TAA-specific T-cell repertoire,
especially T-cells with high affinity for its peptide epi-
tope. However, it appears that tolerance induction by
the tumors expressing, STEAP or EZH2 may not be
leaded, because we observed that cancer patient’s PBMC
could respond to the peptides and produced lympho-
kines. These results suggest that the STEAP- or EZH2-
reactive T-cells are not tolerant and completely deleted
by tumor cells in vivo.
The present study is the first report of the identifica-
tion of an immunogenic epitope of EZH2 recognized by
CD4 T-cell and suggests that EZH2, which is the over-
expressed TAA in LC, could be significant immunogenic
target for inducing both CD4 and CD8 T-cell against
LC. In addition, we present new CD4 T-cell epitope
STEAP281-296, which is closely located in the HLA-A2
restricted CD8 T-cell epitope, STEAP292-300 [21]. Wro-
b l e w s k ie ta ld e m o n s t r a t e dt h a ts o m eL Cc e l ll i n e s
(23%) constitutively express HLA-DR molecules and
treatment of IFN-g could enhance expression of HLA-
DR molecules in LC cells [25]. Another published stu-
dies described that 45% of lung adenocarcinoma
$
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Figure 10 Assessment of cytolytic activity of STEAP281-296-o rE Z H 2 95-109-reactive CD4 T-cell clones. The DR15-restricted, STEAP281-296-
reactive CD4 T-cell clone SH31 (A, left), and DR53-restricted, STEAP281-296-reactive CD4 T-cell clone Sa12 (A, right) were evaluated for their
capacity to kill STEAP-expressing, DR53 positive LC cells (LU65 and Calu-1) or STEAP-expressing, DR53 negative LC cells (EBC1, negative control).
The DR15-restricted, EZH295-109-reactive CD4 T-cell clones SK32 (B, left), Sa361 (B, middle), and DR53-restricted, EZH295-109-reactive CD4 T-cell
clone Sa362 (B, right) were evaluated for their capacity to kill EZH2-expressing, DR15 positive LC cells (LU65 and RERF-LC-AI), DR53 positive LC
cells (LU65 and Calu-1) or EZH2-expressing, DR15 and DR53 negative LC cells (EBC1, negative control). Points means of triplicate determinations,
bars SD. Points without bars had SD < 10% the value of the mean.
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Page 11 of 14Table 1 Assessment of T-cell responses to the STEAP281-296 and EZH295-109-peptides in lung cancer patients and healthy donors.
No. Sex Age
(y)
Pathological
stage
Histological
diagnosis
No antigen
(IFN-g, pg/ml)
No antigen (GM-
CSF, pg/ml)
STEAP281-296
(IFN-g, pg/ml)
STEAP281-296
(GM-CSF, pg/ml)
EZH295-109
(IFN-g, pg/ml)
EZH295-109 (GM-
CSF, pg/ml)
TT830-843
(IFN-g,p g /
ml)
TT830-843 (GM-
CSF, pg/ml)
1 F 61 M1a IV adenocarcinoma < < 259.7 ± 74.6 749.4 ± 196.9 220.8 ± 175.3 968.5 ± 159.7 95.9 ± 9.2 545.7 ± 25.3
2 M 80 T3N0M0 IIB adenosquamous
carcinoma
< < 320.5 ± 267.2 893.0 ± 355.6 565.7 ± 38.0 997.3 ± 27.4 985.1 ± 799.0 1267.8 ± 260.9
3 F 71 T1aN0M0 IA adenocarcinoma 41.0 ± 5.0 35.8 ± 2.5 704.3 ± 502.5 516.0 ± 87.1 1030.0 ± 106.6 147.4 ± 55.7 1004.4 ±
451.3
620.8 ± 472.2
4 M 81 T3N0M0 IIB adenocarcinoma < < 516.8 ± 0 206.0 ± 93.9 94.9 ± 0 65.9 ± 32.3 57.1 ± 25.1 77.9 ± 12.7
5 M 74 T1bN0M0 IA adenocarcinoma < < 31.1 ± 0 135.4 ± 0 31.1 ± 20.1 34.8 ± 0 64.2 ± 0 31.2 ± 0
6 F 69 T3N0M0 IIB adenocarcinoma < < 487.6 ± 444.3 474.9 ± 188.5 473.1 ± 354.0 389.3 ± 70.1 550.3 ± 118.1 917.4 ± 147.4
7 M 74 T2aN0M0 IB basaloid
carcinoma
< < 189.7 ± 76.9 < 152.7 ± 57.5 < 203.9 ± 0 299.7 ± 278.1
8 M 71 T1aN0M0 IA adenocarcinoma < < 173.7 ± 7.3 105.2 ± 49.9 54.3 ± 2.7 158.4 ± 56.7 91.4 ± 62.1 180.8 ± 1.7
9 F 56 T2aN0M0 IB adenocarcinoma < < < < 134.7 ± 0 < 91.9 ± 0 <
10 F 60 T1aN1M0 IIA adenocarcinoma < < < 43.0 ± 38.3 44.2 ± 5.0 287.9 ± 337.1 234.3 ± 91.3 172.3 ± 58.3
11 M 32 - - < < < 440.6 ± 110.0 < 598.9 ± 105.1 < 301.8 ± 52.2
12 M 44 - - < < 214.3 ± 50.6 122.5 ± 20.9 148.2 ± 18.1 < 492.7 ± 312.7 156.7 ± 39.0
13 M 38 - - < < 180.1 ± 45.5 319.6 ± 64.7 190.4 ± 40.2 334.2 ± 57.1 246.8 ± 81.0 414.4 ± 115.1
<: less than the lower limit of detection (mean < 30 pg/ml). No. 1 to 10 are lung cancer patients and No. 11 to 13 are healthy donors. IL-4, Il-5, IL-17, and IL-10 are not detected in all patients and healthy donors.
IFN-g and GM-CSF productions of all above cases were inhibited by anti-HLA-DR mAb L243 (mean < 30 pg/ml).
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4specimens expressed HLA-DR [26] and HLA-DR mole-
cules on primary tumors were detected in 10% of
patients with micrometastasis to regional lymph nodes
and in 30% of patients without tumor spread [27]. We
were also able to verify that the expression of HLA-DR
was found in some lung adenocarcinomas and tumor
adjacent infiltrating APCs (Figure 2). These observations
s u g g e s tt h a tC D 4T - c e l l sh a v ei m p o r t a n tr o l ei ni m m u -
nological response to LC and tumor cells are logical tar-
gets of the TAA-specific CD4 T-cells in vivo.I n
addition, the predicted peptide STEAP281-296 and
EZH295-109 could be capable of stimulating T-cell
responses in some LC patients. Taken together these
results, we believe that the simultaneous induction of
STEAP- and EZH2-specific CD4 and CD8 T-cell
responses would be more effective in achieving anti-
tumor effects than the separate induction of CD4, or
CD8 T-cell responses. Moreover, the recent develop-
ment of EZH2 inhibitors as anti-cancer therapeutics [9]
opens the interesting opportunity of a combined che-
motherapy/immunological approach for treating EZH2-
expressing LCs.
Conclusions
Peptides STEAP281-296 and EZH295-109 are newly
described CD4 T-cell epitopes that can elicit effective
anti-tumor T-cell responses against STEAP or EZH2
expressing LC cell lines. These peptides may facilitate
the development of peptide-based vaccines for LC.
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